MCID: BRS047
MIFTS: 100

Breast Cancer

Categories: Genetic diseases, Rare diseases, Cancer diseases, Reproductive diseases

Aliases & Classifications for Breast Cancer

MalaCards integrated aliases for Breast Cancer:

Name: Breast Cancer 53 12 72 24 71 36 13 51 40 3 14 59
Breast Carcinoma 12 24 71 28 51 14 69
Breast Cancer, Familial 53 72 49 24 69
Male Breast Cancer 12 49 40 14
Malignant Neoplasm of Breast 12 24 69
Breast Cancer, Lobular 53 37 28
Malignant Neoplasm of Male Breast 12 69
Breast Cancer, Susceptibility to 53 28
Invasive Ductal Breast Carcinoma 51 69
Breast Cancer, Invasive Ductal 53 37
Hereditary Breast Carcinoma 49 55
Breast Cancer, Early-Onset 53 28
Familial Breast Carcinoma 49 55
Breast Lobular Carcinoma 12 14
Hereditary Breast Cancer 49 55
Carcinoma of Male Breast 28 69
Familial Breast Cancer 49 55
Breast Cancer, Male 53 49
Mammary Carcinoma 12 71
Mammary Cancer 12 24
Mammary Tumor 12 51
Breast Cancer, Male, Susceptibility to 53
Primary Malignant Neoplasm of Breast 69
Breast Cancer, Protection Against 53
Malignant Tumor of the Breast 12
Breast Cancer Susceptibility 53
Breast Cancer, Familial Male 28
Breast Cancer Familial Male 71
Malignant Tumor of Breast 24
Familial Cancer of Breast 28
Animal Mammary Neoplasms 69
Neoplasm of Male Breast 12
Heritable Breast Cancer 49
Breast Cancer, Somatic 53
Breast Cancer Familial 71
Neoplasm of the Breast 28
Breast Neoplasms, Male 41
Primary Breast Cancer 12
Male Breast Carcinoma 49
Genetic Breast Cancer 49
Breast Male Carcinoma 51
Breast Cancer in Men 49
Carcinoma of Breast 12
Mammary Neoplasms 69
Mammary Neoplasm 12
Cancer of Breast 24
Breast Neoplasms 41
Breast Tumor 12
Bc 71

Characteristics:

OMIM:

53
Inheritance:
autosomal dominant

Miscellaneous:
genetic heterogeneity


HPO:

31
breast cancer:
Inheritance autosomal dominant inheritance heterogeneous


Classifications:



Summaries for Breast Cancer

NIH Rare Diseases : 49 Familial breast cancer is a cluster of breast cancer within a family. Most cases of breast cancer occur sporadically in people with little to no family history of the condition. Approximately 5-10% of breast cancer is considered "hereditary" and is thought to be caused by an inherited predisposition to breast cancer that is passed down through a family in an autosomal dominant manner. In some of these families, the underlying genetic cause is not known; however, many of these cases are caused by changes (mutations) in the BRCA1, BRCA2, PTEN, TP53, CDH1, or STK11 genes (which are each associated with a unique hereditary cancer syndrome). Additional genes, such as CHEK2, BRIP1, RAD51, and ATM, are associated with breast and/or gynecologic cancers in some cases. About 15-20% of women diagnosed with breast cancer have a significant family history of breast cancer (two or more first-degree or second-degree relatives with breast cancer) but have no identifiable mutation in a gene known to cause a hereditary predisposition to breast cancer. These clusters of breast cancer are likely due to a combination of gene(s) and other shared factors such as environment and lifestyle.High-risk cancer screening and other preventative measures such as chemoprevention and/or prophylactic surgeries are typically recommended in women who have an increased risk for breast cancer based on their personal and/or family histories. Last updated: 8/30/2017

MalaCards based summary : Breast Cancer, also known as breast carcinoma, is related to bilateral breast cancer and sporadic breast cancer, and has symptoms including breast carcinoma, pain and lameness, animal. An important gene associated with Breast Cancer is BRCA2 (BRCA2, DNA Repair Associated), and among its related pathways/superpathways are Breast cancer and MicroRNAs in cancer. The drugs Abraxane and Afinitor have been mentioned in the context of this disorder. Affiliated tissues include breast, bone and lymph node, and related phenotypes are Decreased homologous recombination repair frequency and Decreased homologous recombination repair frequency

OMIM : 53 Breast cancer (referring to mammary carcinoma, not mammary sarcoma) is histopathologically and almost certainly etiologically and genetically heterogeneous. Important genetic factors have been indicated by familial occurrence and bilateral involvement. (114480)

UniProtKB/Swiss-Prot : 71 Breast cancer: A common malignancy originating from breast epithelial tissue. Breast neoplasms can be distinguished by their histologic pattern. Invasive ductal carcinoma is by far the most common type. Breast cancer is etiologically and genetically heterogeneous. Important genetic factors have been indicated by familial occurrence and bilateral involvement. Mutations at more than one locus can be involved in different families or even in the same case.

MedlinePlus : 40 Breast cancer affects one in eight women during their lives. No one knows why some women get breast cancer, but there are many risk factors. Risks that you cannot change include Age - the risk rises as you get older Genes - two genes, BRCA1 and BRCA2, greatly increase the risk. Women who have family members with breast or ovarian cancer may wish to be tested for the genes. Personal factors - beginning periods before age 12 or going through menopause after age 55 Other risks include obesity, using hormone replacement therapy (also called menopausal hormone therapy), taking birth control pills, drinking alcohol, not having children or having your first child after age 35, and having dense breasts. Symptoms of breast cancer may include a lump in the breast, a change in size or shape of the breast, and discharge from a nipple. Breast self-exams and mammography can help find breast cancer early, when it is most treatable. One possible treatment is surgery. It could be a lumpectomy or a mastectomy. Other treatments include radiation therapy, chemotherapy, hormone therapy, and targeted therapy. Targeted therapy uses substances that attack cancer cells without harming normal cells. Men can have breast cancer, too, but it is rare. NIH: National Cancer Institute

CDC : 3 Breast cancer is a group of diseases that affects breast tissue. Both women and men can get breast cancer, though it is much more common in women. Other than skin cancer, breast cancer is the most common cancer among women in the United States. Some women are at higher risk for breast cancer than others because of their personal or family medical history or because of certain changes in their genes.

Genetics Home Reference : 24 Breast cancer is a disease in which certain cells in the breast become abnormal and multiply uncontrollably to form a tumor. Although breast cancer is much more common in women, this form of cancer can also develop in men. In both women and men, the most common form of breast cancer begins in cells lining the milk ducts (ductal cancer). In women, cancer can also develop in the glands that produce milk (lobular cancer). Most men have little or no lobular tissue, so lobular cancer in men is very rare.

Disease Ontology : 12 A thoracic cancer that originates in the mammary gland.

Novus Biologicals : 52 Breast cancer is a malignant tumor that originates from breast tissue cells. Although most breast cancers initiate in the cells that line the breast ducts, some begin in the breast lobules and other tissues. As with all cancers, there is a genetic and environmental component of developing breast cancer. Women with defects in the BRCA1 and BRCA2 genes have up to an 80% chance of getting breast cancer. Research has also found that defects in the ErbB-2 gene lead to increased levels of the protein cyclin D1. Cyclin D1 then activates CDK4, which causes proliferation of cellular division. Blocking CDK4 activity may lead to effective breast cancer treatments.

PubMed Health : 59
About breast cancer: Being diagnosed with breast cancer often comes as a shock at first, and makes people feel very frightened and anxious. Having cancer can really turn your life upside down for a while. It helps to know that if you get breast cancer for the first time and it hasn’t spread far, there’s a good chance that treatment can lead to full recovery. There are also many support services that help people in everyday life, to return to work and cope emotionally with breast cancer.

Wikipedia : 72 Breast cancer is cancer that develops from breast tissue. Signs of breast cancer may include a lump in... more...

Related Diseases for Breast Cancer

Diseases in the Breast Cancer family:

Breast Benign Neoplasm Inflammatory Breast Carcinoma
Sporadic Breast Cancer Breast Carcinoma in Situ

Diseases related to Breast Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 824)
# Related Disease Score Top Affiliating Genes
1 bilateral breast cancer 35.6 ATM BRCA1 BRCA2 CHEK2 ESR1 RAD51
2 sporadic breast cancer 35.5 ATM BARD1 BRCA1 BRCA2 CHEK2 ESR1
3 female breast cancer 35.2 ATM BRCA2 ESR1 PALB2 PHB TP53
4 estrogen-receptor positive breast cancer 35.0 AKT1 ESR1 PIK3CA TP53
5 li-fraumeni syndrome 34.1 ATM BRCA1 BRCA2 CHEK2 TP53
6 breast metaplastic carcinoma 34.0 CDH1 ESR1 TP53
7 breast-ovarian cancer, familial 1 33.6 BRCA1 BRCA2
8 hereditary breast ovarian cancer syndrome 33.5 BARD1 BRCA1 BRCA2 BRIP1 CHEK2 PALB2
9 ovarian cancer 33.2 AKT1 BARD1 BRCA1 BRCA2 BRIP1 CDH1
10 li-fraumeni syndrome 2 33.2 CHEK2 TP53
11 brca1 hereditary breast and ovarian cancer syndrome 33.1 BRCA1 BRCA2
12 ductal carcinoma in situ 32.8 AKT1 BRCA1 BRCA2 CDH1 ESR1 TP53
13 prostate cancer 32.6 AKT1 BRCA1 BRCA2 CDH1 CHEK2 ESR1
14 fanconi anemia, complementation group a 32.3 ATM BRCA1 BRCA2 BRIP1 PALB2 RAD51
15 endometrial cancer 32.2 AKT1 BRCA1 BRCA2 CDH1 ESR1 PIK3CA
16 ataxia-telangiectasia 32.1 ATM BRCA1 CHEK2 TP53
17 pancreatic cancer 31.9 AKT1 BRCA1 BRCA2 CDH1 PALB2 PIK3CA
18 breast reconstruction 31.9 BRCA1 BRCA2
19 ovarian cancer 1 31.8 AKT1 BRCA1 BRCA2 CDH1 ESR1 PIK3CA
20 breast ductal carcinoma 31.8 BRCA1 CDH1 ESR1 RAD54L TP53
21 wilms tumor 1 31.7 BRCA2 CHEK2 ESR1 TP53
22 in situ carcinoma 31.6 BRCA1 CDH1 ESR1 TP53
23 mutagen sensitivity 31.6 BRCA1 BRCA2 TP53 XRCC3
24 nijmegen breakage syndrome 31.6 ATM BRCA1 CHEK2 TP53
25 cowden disease 31.6 AKT1 BRCA1 BRCA2 PIK3CA
26 breast carcinoma in situ 31.4 BRCA1 BRCA2 ESR1 TP53
27 glioblastoma 31.3 AKT1 BRCA2 PIK3CA TP53
28 esophageal cancer 31.3 AKT1 CDH1 CHEK2 PIK3CA RAD51 TP53
29 lobular neoplasia 31.1 BRCA1 CDH1 ESR1
30 bloom syndrome 31.0 ATM BRCA1 RAD51
31 pancreatic ductal adenocarcinoma 30.6 AKT1 CDH1 TP53
32 breast cancer-related regulator of tp53 12.2
33 breast cancer, childhood 12.1
34 estrogen-receptor negative breast cancer 12.1
35 progesterone-receptor positive breast cancer 12.0
36 progesterone-receptor negative breast cancer 12.0
37 triple-receptor negative breast cancer 12.0
38 inflammatory breast carcinoma 12.0
39 her2-receptor positive breast cancer 11.9
40 her2-receptor negative breast cancer 11.9
41 gastric cancer, hereditary diffuse 11.8
42 brittle cornea syndrome 2 11.6
43 breast-ovarian cancer, familial 2 11.5
44 breast-ovarian cancer, familial 3 11.5
45 breast-ovarian cancer, familial 4 11.5
46 female reproductive organ cancer 11.5 AKT1 BRCA1 BRCA2 CDH1 ESR1 PIK3CA
47 androgen insensitivity, partial 11.5
48 malignant ovarian surface epithelial-stromal neoplasm 11.4 AKT1 BRCA1 BRCA2 CDH1 PIK3CA TP53
49 ovary epithelial cancer 11.4 AKT1 BRCA1 BRCA2 CDH1 PIK3CA TP53
50 reproductive organ cancer 11.4 AKT1 BRCA1 BRCA2 CDH1 ESR1 TP53

Graphical network of the top 20 diseases related to Breast Cancer:



Diseases related to Breast Cancer

Symptoms & Phenotypes for Breast Cancer

Symptoms via clinical synopsis from OMIM:

53
Neoplasia:
breast carcinoma


Clinical features from OMIM:

114480

Human phenotypes related to Breast Cancer:

31
# Description HPO Frequency HPO Source Accession
1 breast carcinoma 31 HP:0003002

UMLS symptoms related to Breast Cancer:


pain, lameness, animal, pelvic pain

GenomeRNAi Phenotypes related to Breast Cancer according to GeneCards Suite gene sharing:

25 (show all 19)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased homologous recombination repair frequency GR00151-A-1 10.77 BARD1 RAD51 BRCA1
2 Decreased homologous recombination repair frequency GR00151-A-2 10.77 RAD51 BRCA1
3 Decreased homologous recombination repair frequency GR00236-A-1 10.77 BRCA2 PALB2 RAD51 BARD1 TSG101 BRCA1
4 Decreased homologous recombination repair frequency GR00236-A-2 10.77 BRCA2 PALB2 BARD1 RAD51 TSG101 BRCA1
5 Decreased homologous recombination repair frequency GR00236-A-3 10.77 BRCA2 PALB2 BARD1 RAD51 BRCA1
6 Decreased viability GR00055-A-2 10.61 PIK3CA
7 Decreased viability GR00221-A-1 10.61 ESR1 AKT1 PIK3CA
8 Decreased viability GR00221-A-2 10.61 ESR1 BRCA1 CHEK2 AKT1 PIK3CA
9 Decreased viability GR00221-A-3 10.61 BRCA1 CHEK2 AKT1 ATM
10 Decreased viability GR00221-A-4 10.61 ESR1 CHEK2 AKT1 PIK3CA ATM
11 Decreased viability GR00301-A 10.61 BRCA1
12 Decreased viability GR00342-S-2 10.61 CHEK2
13 Decreased viability in esophageal squamous lineage GR00235-A 10.1 CDH1 CHEK2 ESR1 BRCA2 RAD51 TSG101
14 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 10.02 PALB2 CHEK2 BRCA2 AKT1 TSG101 BRCA1
15 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 10.02 BRIP1 PALB2 CHEK2 BRCA2 TSG101 AKT1
16 Decreased ionizing radiation sensitivity GR00232-A-1 10.01 BRCA2 BRIP1 CDH1 BRCA1 AKT1 BARD1
17 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.93 BRIP1 PALB2 CHEK2 BRCA2 TSG101 BRCA1
18 Decreased viability with cisplatin GR00101-A-4 9.65 BRIP1 BRCA2 BRCA1 BARD1 RAD51
19 Synthetic lethal with cisplatin GR00101-A-1 9.43 BRIP1 BRCA2 BRCA1 BARD1 RAD51 XRCC3

MGI Mouse Phenotypes related to Breast Cancer:

43 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.41 CDH1 PALB2 CHEK2 PIK3CA ESR1 TSG101
2 endocrine/exocrine gland MP:0005379 10.29 HMMR CDH1 PHB CHEK2 PIK3CA ESR1
3 homeostasis/metabolism MP:0005376 10.28 BRIP1 CDH1 CHEK2 PHB ESR1 ATM
4 embryo MP:0005380 10.27 CDH1 PALB2 PIK3CA ESR1 ATM BRCA2
5 growth/size/body region MP:0005378 10.27 ESR1 CDH1 PALB2 PHB ATM RAD51
6 mortality/aging MP:0010768 10.25 CDH1 PALB2 PHB CHEK2 PIK3CA ESR1
7 immune system MP:0005387 10.18 ESR1 CDH1 CHEK2 PIK3CA ATM BRCA2
8 integument MP:0010771 10.15 CDH1 PALB2 PHB PIK3CA ESR1 ATM
9 neoplasm MP:0002006 10.1 CDH1 HMMR PALB2 CHEK2 PIK3CA ESR1
10 nervous system MP:0003631 9.9 BRIP1 ESR1 PALB2 CHEK2 PIK3CA ATM
11 normal MP:0002873 9.61 ESR1 CDH1 BRCA2 TSG101 BARD1 RB1CC1
12 reproductive system MP:0005389 9.36 HMMR CDH1 PHB ESR1 BRIP1 ATM

Drugs & Therapeutics for Breast Cancer

PubMedHealth treatment related to Breast Cancer: 59

The treatment options always depend on the type and size of the tumor, where it has spread to (if it has spread), the patient’s general health, as well as their personal preferences. Breast cancer can be treated with surgery, radiation and medication. Different treatment approaches are often combined.The standard treatment is to try to surgically remove as much of the tumor as possible. Neighboring lymph nodes are sometimes also removed. If the tumor is small, women are often faced with a decision: Should they keep the breast or have it completely removed? Nowadays many women can have surgery that allows them to keep the breast (breast-conserving surgery). But sometimes the entire breast needs to be removed (mastectomy) to make sure that all of the tumor tissue has gone.Chemotherapy (treatment with medication) is sometimes used to shrink larger tumors before surgery and make it easier to operate on them. This kind of treatment is called “neoadjuvant chemotherapy.”Chemotherapy is sometimes used after surgery too. Women who have a hormone-sensitive tumor may have anti-hormonal therapy. This aims to slow down tumor growth.After breast-conserving surgery the surrounding tissue is exposed to radiation, if possible, so that any remaining tumor cells can be destroyed. This is sometimes necessary after a mastectomy as well. Radiotherapy is also commonly used if the tumor cannot be surgically removed.The different types of treatment can be very difficult to go through and sometimes have very severe side effects or cause other medical problems. The side effects vary depending on the kind of treatment, but they are often easy to treat. The treatment of side effects is part of what is known as supportive care.Before deciding on whether to have a particular treatment, there is usually enough time to get information from your doctor about the possible benefits and the expected side effects, and to talk with your family or other people who are close to you. You have the right to seek a second opinion from another doctor or to decide not to have a treatment.

FDA approved drugs:

(show all 31)
# Drug Name Active Ingredient(s) 17 Company Approval Date
1
Abraxane 17 45 PACLITAXEL Celgene October 2012
2
Afinitor 17 45 EVEROLIMUS Novartis March 2009
3
Aredia 17 45 PAMIDRONATE DISODIUM Chiron August 1996
4
Arimidex 17 45 ANASTROZOLE AstraZeneca January 1996
5
Aromasin Tablets 17 45 EXEMESTANE Pharmacia & Upjohn October 21. 1999
6
CEA-Scan 17 Immunomedics April 1996
7
Ellence 17 45 EPIRUBICIN HYDROCHLORIDE Pharmacia & Upjohn September 1999
8
Evista 17 45 RALOXIFENE HYDROCHLORIDE Eli Lilly September 2007
9
Faslodex 17 45 FULVESTRANT AstraZeneca April 2002
10
Femara 17 45 LETROZOLE Novartis January 2001
11
Halaven 17 45 ERIBULIN MESYLATE Eisai November 2010
12
Herceptin 17 45 TRASTUZUMAB Genentech October 1998
13
Ibrance 17 45 PALBOCICLIB Pfizer February 2015
14
Inform HER-2/neu breast cancer test 17 Oncor January 1998
15
Iressa 17 45 GEFITINIB AstraZeneca May 2003
16
Ixempra 17 45 IXABEPILONE Bristol-Myers Squibb October 2007
17
Kadcyla 17 45 ADO-TRASTUZUMAB EMTANSINE Genentech February 2013
18
Miraluma Test 17 TECHNETIUM TC-99M SESTAMIBI KIT DuPont Merck Pharmaceutical Company May 1997
19
Neulasta 17 PEGFILGRASTIM Amgen January 2002
20
Neutroval 17 tbo-filgrastim Teva Pharmaceutical August 2012
21
Nolvadex 17 45 TAMOXIFEN CITRATE AstraZeneca October 1998
22
Perjeta 17 45 PERTUZUMAB Genentech June 2012
23
Premarin 17 ESTROGENS CONJUGATED Wyeth July of 2003
24
Self-examination breast pad 17 Inventive Products on December 22, 1995
25
Taxol 17 45 PACLITAXEL Bristol-Myers Squibb August 1997
26
Taxotere 17 45 DOCETAXEL Rhone Poulenc Rorer May 1996
27
Tykerb 17 45 LAPATINIB DITOSYLATE GlaxoSmithKline March 2007
28
Xeloda 17 45 CAPECITABINE Roche April 1998/ May 2001
29
Xgeva 17 45 DENOSUMAB Amgen June 2013/ November 2010
30
Zoladex 17 45 GOSERELIN ACETATE AstraZeneca January 1996
31
Zometa 17 45 ZOLEDRONIC ACID Novartis August 2001/ February 2002

Drugs for Breast Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1124)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Letrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 112809-51-5 3902
2
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 33069-62-4 36314
3
Zoledronic acid Approved Phase 4,Phase 2,Phase 3,Phase 1 118072-93-8 68740
4
Toremifene Approved, Investigational Phase 4,Phase 3,Phase 2 89778-26-7 3005573
5
Anastrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 120511-73-1 2187
6
Exemestane Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 107868-30-4 60198
7
Tamoxifen Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 10540-29-1 2733526
8
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 439-14-5 3016
9
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 41575-94-4 10339178 38904 498142
10
Epirubicin Approved Phase 4,Phase 3,Phase 2,Phase 1 56420-45-2 41867
11
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 135968-09-1
12
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
13
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
14
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1 51-21-8 3385
15
Chlorhexidine Approved, Vet_approved Phase 4,Phase 2 55-56-1 2713 9552079
16
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 64-17-5 702
17
Iodine Approved, Investigational Phase 4,Phase 2,Phase 1,Early Phase 1 7553-56-2 807
18
Povidone Approved Phase 4,Phase 2 9003-39-8
19
Povidone-iodine Approved Phase 4,Phase 3 25655-41-8
20
Acetaminophen Approved Phase 4,Phase 3,Phase 2,Phase 1 103-90-2 1983
21
Bupivacaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 38396-39-3, 2180-92-9 2474
22 Cisatracurium Approved, Experimental Phase 4 96946-41-7
23
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Early Phase 1 51-43-4 5816
24
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 437-38-7 3345
25
Ketorolac Approved Phase 4,Phase 3,Phase 2 74103-06-3, 66635-83-4 3826
26
Morphine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 57-27-2 5288826
27
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 2078-54-8 4943
28 Racepinephrine Approved Phase 4,Phase 3,Phase 2,Early Phase 1 329-65-7
29
Iron Approved Phase 4,Phase 3,Phase 2,Early Phase 1 7439-89-6 23925
30
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 83-43-2 6741
31
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-24-8 5755
32
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 124-94-7 31307
33
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-28-2 5757
34
Medroxyprogesterone acetate Approved, Investigational Phase 4,Phase 3,Phase 2 71-58-9
35
Progesterone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 57-83-0 5994
36
Ketamine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 6740-88-1 3821
37
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-02-2 5743
38
Ondansetron Approved Phase 4,Phase 3,Phase 2 99614-02-5 4595
39
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1 159351-69-6 6442177
40
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
41
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53123-88-9 46835353 6436030 5284616
42
Capecitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 154361-50-9 60953
43
Trastuzumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 180288-69-1 9903
44
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 216974-75-3
45
Vinblastine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 865-21-4 241903 13342
46
Vinorelbine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 71486-22-1 44424639 60780
47
Nitrous oxide Approved, Vet_approved Phase 4,Phase 3 10024-97-2 948
48
Ropivacaine Approved Phase 4,Phase 3,Phase 2,Early Phase 1 84057-95-4 175805 71273
49
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 1994-09-7, 94-09-7 2337
50
Sevoflurane Approved, Vet_approved Phase 4,Phase 3,Phase 2 28523-86-6 5206

Interventional clinical trials:

(show top 50) (show all 8512)

# Name Status NCT ID Phase Drugs
1 Benefits of Breast MRI for Predicting of Histopathologic Cell Type of Small Breast Cancer Unknown status NCT01597999 Phase 4
2 Assessment of Quality of Life, Bone Density and Safety in Postmenopausal Breast Cancer Patients With Letrozole Therapy Unknown status NCT00913016 Phase 4
3 A Clinical Trial of Paclitaxel Loaded Polymeric Micelle in Patients With Taxane-Pretreated Recurrent Breast Cancer Unknown status NCT00912639 Phase 4 Paclitaxel loaded Polymeric micelle
4 Proton MR Spectroscopy and 18F-Fluorocholine PET for Breast Cancer Diagnosis Unknown status NCT01956409 Phase 4 18F-FCH;Magnevist
5 Evaluate the Relationship of Bone Remodeling Markers for Skeletal Complications in Metastatic Breast Cancer Patients Unknown status NCT00912938 Phase 4 zoledronic acid
6 Clinical Outcomes After Letrozole Treatment According to the Estrogen Receptor Expression in Postmenopausal Women Unknown status NCT01069211 Phase 4
7 Extended Adjuvant Treatment With Letrozole in Breast Cancer Who Complete 5 Years of Toremifene Unknown status NCT01072318 Phase 4 Letrozole
8 Omega-3 Fatty Acids and Chemotherapy-induced Neuropathy and Inflammation in Breast Cancer Unknown status NCT01049295 Phase 4
9 Circulating miRNAs as Biomarkers of Hormone Sensitivity in Breast Cancer Unknown status NCT01612871 Phase 4 Tamoxifen, Letrozole , Anastrozole, Exemestane
10 Study the Role of Positron Emission Mammography in Pre-surgical Planning for Breast Cancer Unknown status NCT00484614 Phase 4
11 Yunzhi as Dietary Supplement in Breast Cancer Unknown status NCT00647075 Phase 4
12 Paclitaxel in Combination With Carboplatin Versus Paclitaxel Plus Epirubicin in Metastatic Breast Cancer Unknown status NCT02207361 Phase 4 Paclitaxel, Carboplatin;Paclitaxel, Epirubicin
13 Filgrastim or Pegfilgrastim in Preventing Neutropenia in Women Receiving Chemotherapy Following Surgery for Breast Cancer Unknown status NCT00030758 Phase 4
14 Evaluation of Predictive Factors Regarding the Effectivity of Aromatase Inhibitor Therapy (PreFace) Unknown status NCT01908556 Phase 4 Letrozole
15 Study of the Effect of Glutamine Supplementation on Chemotherapy Induced Toxicities in Breast Cancer Patients Unknown status NCT00772824 Phase 4
16 A Study of Liposomal Doxorubicin in Women With Breast Cancer Exploiting Tissue Doppler Imaging Unknown status NCT00531973 Phase 4 liposomal doxorubicin;epirubicin
17 STARS Breast Trial (Study of Anastrozole and Radiotherapy Sequencing Pilot) Unknown status NCT00126360 Phase 4 Timing of Anastrozole in respect to radiotherapy
18 Wound Infections in Breast Cancer Surgery After Preoperative Skin Preparation With Chlorhexidine vs. Povidone-iodine Unknown status NCT02479347 Phase 4 Chlorhexidine;Povidone-Iodine
19 Weekly and Every 3 Week Administration of Paclitaxel Liposome Injection in Metastatic Breast Cancer Unknown status NCT02142790 Phase 4 paclitaxel liposome injection
20 National Screening in Denmark With MR Versus Mammography and Ultrasound of Women With BRCA1 or BRCA2 Mutations Unknown status NCT00413491 Phase 4
21 The MONET - Study: MR Mammography of Nonpalpable Breast Tumors Unknown status NCT00302120 Phase 4
22 Contrast The Role of Avitene And OK-432 in Reducing Seroma Formation After Axillary Lymphadenectomy for Breast Cancer Unknown status NCT02158299 Phase 4 Avitene;Sapylin
23 Clinical Trial Comparing Outcomes of Breast Conserving Operations With Classic v High-frequency Electrocoagulation Unknown status NCT01216254 Phase 4
24 18F-FLT Positron Emission Tomography and Magnetic Resonance Imaging of the Breast Unknown status NCT01956890 Phase 4 PET
25 Serratus Anterior Plane Block Versus Paravertebral Block for Postmastectomy Analgesia Unknown status NCT02103946 Phase 4
26 Sienna+® Injection Time Study 4 Arms Unknown status NCT02612870 Phase 4
27 Does a Single Steroid Injection Reduce the Formation of Postmastectomy Seroma Unknown status NCT00307606 Phase 4 Solu-medrol 125 mg
28 Prevention of Neutropenia After Using G-CSF With TAC Chemotherapy Unknown status NCT01571518 Phase 4 late leukostim;early leukostim
29 Aromatase Inhibitor Clinical Trial Unknown status NCT00228956 Phase 4 pharmacodynamic analysis
30 Multi-centre Clinical Trial on Hormone Replacement Treatment in China Unknown status NCT01698164 Phase 4 estradiol plus MPA;Ximingting Tablet;estradiol plus progesterone
31 Effect of Ketalar to Prevent Postoperative Chronic Pain After Mastectomy Unknown status NCT00129597 Phase 4 ketalar
32 Changes in Knee Articular Cartilage Volume in Women on Aromatase Inhibitors Unknown status NCT00111241 Phase 4 aromatase inhibitors (letrozole, anastrozole)
33 WHAT (Women, Hot-flashes, Activity, Trial) - Physical Activity for Treatment of Hot Flushes Among Postmenopausal Women Unknown status NCT01282320 Phase 4
34 Intraoperative Ketamine on Chronic Pain After Mastectomy Unknown status NCT02729805 Phase 4 Saline;Ketamine 0.5mg/kg;Ketamine 0.75mg/kg
35 Case-Control-Study on the Breast Cancer Risk of Mirena® Compared With Copper IUDs Completed NCT00461253 Phase 4
36 Incidence of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With the Docetaxel-Cyclophosphamide Regimen in Early Breast Cancer Patients Completed NCT01298193 Phase 4 Aprepitant
37 An Open Label Study of Postmenopausal Women With Oestrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) With Exemestane, With Exploratory Epigenetic Marker Analysis Completed NCT01743560 Phase 4 RAD001;Exemestane
38 Randomized Trial of Follow-up Strategies in Breast Cancer Completed NCT00156039 Phase 4
39 Research Of Quality Of Life And Safety Outcomes Of Postmenopausal Breast Cancer Patients Switching From Tamoxifen Therapy To Aromatase Inhibitor Therapy Completed NCT00784888 Phase 4
40 Pamidronate Administration in Breast Cancer Patients With Bone Metastases Completed NCT00128297 Phase 4 Pamidronate
41 Open Label Study of Postmenopausal Women With ER and /or PgR Positive Breast Cancer Treated With Letrozole Completed NCT00237224 Phase 4 Letrozole
42 Prospective Validation Trial of Circulating Tumor Cells (CTCs) in Women With Metastatic Breast Cancer Completed NCT00493350 Phase 4
43 Life Quality and Mental State in Patients With Breast Cancer Completed NCT01458457 Phase 4
44 Maintenance Treatment With Liposomal Doxorubicin (Caelyx) in Metastatic Breast Cancer Patients Completed NCT00128778 Phase 4 Pegylated liposomal doxorubicin (Caelyx)
45 Will Preoperative MRI Breast in Women Under 56 Years With Breast Cancer Change Primary Treatment Completed NCT01859936 Phase 4
46 Comparative Efficiency of Three Regimen, CEFci, CEF and EC as Neoadjuvant Chemotherapy for Primary Breast Cancer Completed NCT01199432 Phase 4 5-FU(intravenous infusion)+epirubicin+cyclophosphamide;5-FU(intravenous bolus)+epirubicin+cyclophosphamide;epirubicin+cyclophosphamide
47 Pharmacology of Adjuvant Hormonotherapy in Breast Cancer Completed NCT01127295 Phase 4 Tamoxifen, Letrozole, Anastrozole or Exemestane
48 Feasibility Study for the Determination of Oxysterols in Patients With Breast Cancer Receiving Hormonal Therapy With Tamoxifen or Not Completed NCT01553903 Phase 4 Tamoxifen,;Exemestane;Anastrozole;Letrozole
49 Wellbutrin XL, Major Depressive Disorder and Breast Cancer Completed NCT00234195 Phase 4 bupropion extended release (Wellbutrin XL)
50 Eribulin Mesylate Phase IV Clinical Trial in Korean Patients With Metastatic or Locally Advanced Breast Cancer Completed NCT01961544 Phase 4 Eribulin mesylate

Search NIH Clinical Center for Breast Cancer

Inferred drug relations via UMLS 69 / NDF-RT 47 :